ImmuCell (NASDAQ:ICCC) Stock Price Crosses Below 200-Day Moving Average – Time to Sell?

ImmuCell Corporation (NASDAQ:ICCC)’s stock price passed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.15 and traded as low as $5.80. ImmuCell shares last traded at $5.82, with a volume of 45,363 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d+)” rating on shares of ImmuCell in a research note on Monday. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, ImmuCell presently has a consensus rating of “Sell”.

ImmuCell Stock Down 0.7%

The firm’s 50-day moving average price is $5.70 and its 200 day moving average price is $6.15. The company has a market capitalization of $52.30 million, a price-to-earnings ratio of 22.23 and a beta of 0.20. The company has a current ratio of 4.21, a quick ratio of 1.76 and a debt-to-equity ratio of 0.27.

ImmuCell (NASDAQ:ICCC) last posted its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter. ImmuCell had a return on equity of 8.00% and a net margin of 8.37%.The firm had revenue of $5.51 million for the quarter.

Hedge Funds Weigh In On ImmuCell

An institutional investor recently raised its position in ImmuCell stock. Geode Capital Management LLC boosted its holdings in ImmuCell Corporation (NASDAQ:ICCC) by 4.2% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 71,852 shares of the biotechnology company’s stock after buying an additional 2,907 shares during the quarter. Geode Capital Management LLC owned approximately 0.79% of ImmuCell worth $500,000 at the end of the most recent reporting period. 13.47% of the stock is currently owned by institutional investors and hedge funds.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.